Literature DB >> 27165625

What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?

C Sonigo1, C Simon2, M Boubaya3, A Benoit2, C Sifer4, N Sermondade4, M Grynberg5.   

Abstract

STUDY QUESTION: What threshold values of ultrasonographic antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) levels should be considered for ensuring the cryopreservation of sufficient number of in vitro matured (IVM) oocytes, in cancer patients seeking fertility preservation (FP)? SUMMARY ANSWER: AFC and serum AMH values >20 follicles and 3.7 ng/ml, respectively, are required for obtaining at least 10 IVM oocytes for cryopreservation. WHAT IS KNOWN ALREADY: IVM of cumulus oocyte complexes (COCs) followed by oocyte cryopreservation has emerged recently as an option for urgent FP. Recent data have reported that, in healthy patients, 8-20 cryopreserved oocytes after ovarian stimulation would maximize the chance of obtaining a live birth. Although both AFC and AMH have been reported as predictive factors of IVM success in infertile patients with polycystic ovary syndrome (PCOS), there is a dramatic lack of data regarding the values of these parameters in oncological patients as candidates for FP. STUDY DESIGN, SIZE, DURATION: From January 2009 to April 2015, we prospectively studied 340 cancer patients, aged 18-41 years, as candidates for oocyte cryopreservation following IVM. PARTICIPANTS/MATERIALS, SETTING,
METHODS: All patients had AFC and AMH measurements, 48-72 h before oocyte retrieval, regardless of the phase of the cycle. COCs were recovered under ultrasound guidance 36 h after hCG priming. Logistic regression allowed the determination of threshold values of AFC and AMH, for obtaining at least 8, 10 or 15 matures oocytes frozen after the IVM procedure. Similar analyses were performed for a final number of mature oocytes ≤2. MAIN RESULTS AND THE ROLE OF CHANCE: Among the 340 cancer patients included, 300 were diagnosed with breast cancers, 14 had hematological malignancies and 26 underwent the procedure for others indications. Overall, the mean age of the population was 31.8 ± 4.5 years. Mean AFC and serum AMH levels were 21.7 ± 13.3 follicles and 4.4 ± 3.8 ng/ml, respectively. IVM was performed in equal proportions during the follicular or luteal phase of the cycle (49 and 51%, respectively). Statistical analysis showed that AFC and AMH values above 28 follicles and 3.9 ng/ml, 20 follicles and 3.7 ng/ml and 19 follicles and 3.5 ng/ml are required, respectively, for obtaining at least 15, 10 or 8 frozen IVM oocytes with a sensitivity ranging from 0.82 to 0.90. On the contrary, ≤2 IVM oocytes were cryopreserved when AFC and AMH were <19 follicles and 3.0 ng/ml, respectively. LIMITATIONS, REASONS FOR CAUTION: Although the potential of cryopreserved IVM oocytes from cancer patients remains unknown, data obtained from infertile PCOS women have shown a dramatically reduced competence of these oocytes when compared with that of oocytes recovered after ovarian stimulation. As a consequence, the optimal number of IVM oocytes frozen in candidates for FP is currently unpredictable. WIDER IMPLICATIONS OF THE
FINDINGS: Cryopreservation of oocytes after IVM should be considered in the FP strategy when ovarian stimulation is unfeasible, in particular when markers of the follicular ovarian status are at a relatively high range. Further investigation is needed to objectively assess the real potential of these IVM oocytes after cryopreservation. Therefore, even when a good COCs yield is expected, we should systematically encourage IVM in combination with ovarian tissue cryopreservation. STUDY FUNDING/COMPETING INTERESTS: No external funding was obtained for the present study. The authors have no conflict of interest to declare. TRIAL REGISTRATION NUMBER: Not applicable.
© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  AMH; antral follicle count; fertility preservation; in vitro maturation; oocytes cryopreservation

Mesh:

Substances:

Year:  2016        PMID: 27165625     DOI: 10.1093/humrep/dew102

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation.

Authors:  Alon Kedem; Gil M Yerushalmi; Masha Brengauz; Hila Raanani; Raoul Orvieto; Ariel Hourvitz; Dror Meirow
Journal:  J Assist Reprod Genet       Date:  2018-03-24       Impact factor: 3.412

Review 2.  In vitro maturation of human immature oocytes for fertility preservation and research material.

Authors:  Hiromitsu Shirasawa; Yukihiro Terada
Journal:  Reprod Med Biol       Date:  2017-06-18

Review 3.  Perspectives on the development and future of oocyte IVM in clinical practice.

Authors:  Michel De Vos; Michaël Grynberg; Tuong M Ho; Ye Yuan; David F Albertini; Robert B Gilchrist
Journal:  J Assist Reprod Genet       Date:  2021-07-03       Impact factor: 3.412

4.  Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: a retrospective study of ten years of experience.

Authors:  Charlotte Sonigo; Nelly Frydman; Anne Mayeur; Vincent Puy; Victoria Windal; Laetitia Hesters; Vanessa Gallot; Alexandra Benoit; Michael Grynberg
Journal:  J Assist Reprod Genet       Date:  2021-04-01       Impact factor: 3.357

5.  Development of new method and protocol for cryopreservation related to embryo and oocytes freezing in terms of fertilization rate: A comparative study including review of literature.

Authors:  Mayadhar Barik; Minu Bajpai; Santosh Patnaik; Pravash Mishra; Priyamadhaba Behera; Sada Nanda Dwivedi
Journal:  Adv Biomed Res       Date:  2016-07-06

6.  Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible.

Authors:  Nathalie Sermondade; Michaël Grynberg; Marjorie Comtet; Constance Valdelievre; Christophe Sifer; Charlotte Sonigo
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.